MANSFIELD, Mass.--(BUSINESS WIRE)--Apr. 4, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, announced that it has prevailed against Applied Medical Resources Corp. in a patent action before the U.S. District Court, Central District of California.

In granting Covidien’s motion of summary judgment, the District Court ruled that Covidien’s trocar products do not infringe Applied Medical’s patent. In May 2011, Applied Medical sued Covidien in connection with Covidien’s sale of certain trocar products.

“We are pleased that the Court recognized that Covidien’s trocar products are differentiated from our competitors,” said Scott Herring, Vice President, Endomechanical and Energy Division, Covidien Surgical Solutions.

ABOUT COVIDIEN

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2011 revenue of $11.6 billion, Covidien has 41,000 employees worldwide in more than 65 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.

Source: Covidien

Covidien
Marta Newhart, 303-476-7383
Vice President
Communications & Public Affairs
marta.newhart@covidien.com
or
Bruce Farmer, 508-452-4372
Vice President
Public Relations
bruce.farmer@covidien.com
or
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
cole.lannum@covidien.com
or
Todd Carpenter, 508-452-4363
Director
Investor Relations
todd.carpenter@covidien.com